Growth Metrics

Insight Molecular Diagnostics (IMDX) Cash from Investing Activities (2016 - 2026)

Insight Molecular Diagnostics' Cash from Investing Activities history spans 6 years, with the latest figure at -$1.5 million for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 604.29% to -$1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.2 million, a 522.07% decrease, with the full-year FY2025 number at -$3.2 million, down 522.07% from a year prior.
  • Cash from Investing Activities hit -$1.5 million in Q4 2025 for Insight Molecular Diagnostics, down from -$1.0 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for IMDX hit a ceiling of $214000.0 in Q3 2023 and a floor of -$8.3 million in Q1 2021.
  • Historically, Cash from Investing Activities has averaged -$1.1 million across 5 years, with a median of -$397500.0 in 2021.
  • Biggest five-year swings in Cash from Investing Activities: soared 124.91% in 2023 and later crashed 1179.17% in 2025.
  • Tracing IMDX's Cash from Investing Activities over 5 years: stood at -$401000.0 in 2021, then plummeted by 100.0% to -$802000.0 in 2022, then surged by 112.84% to $103000.0 in 2023, then tumbled by 303.88% to -$210000.0 in 2024, then plummeted by 604.29% to -$1.5 million in 2025.
  • Business Quant data shows Cash from Investing Activities for IMDX at -$1.5 million in Q4 2025, -$1.0 million in Q3 2025, and -$349000.0 in Q2 2025.